[Tavanik effectiveness and safety in the treatment of urinary tract infection complications].

20 patients with complicated urinary infection (CUI) have been treated with levofloxacine (tavanik) for 10 days in a single daily dose 250 mg. They were compared with 23 acute pyelonephritis patients given ciprofloxacin in a dose 1 g/day. None of the patients had purulent inflammation or was treated with antibacterial drugs. The response to tavanik and its safety were good or very good in 95% patients. With ciprofloxacin the same results were achieved in 88% patients. 3 patients failed this treatment. 2 patients developed purulent pyelonephritis and were operated. The number and intensity of side effects were higher were less in the tavanik group. Thus, tavanik, a new antibacterial drug from fluoroquinolone group, is effective and low-toxic in complicated infection of the urinary tracts.